[{"from": "human", "value": "Please give me some details about this molecule. [C][C@@H1][C@H1][Branch2][Ring1][N][C@@H1][Branch2][Ring1][#Branch1][C@@H1][Branch1][Ring2][O][Ring1][Branch1][N][C][=N][C][=C][Branch1][=Branch2][N][=C][N][=C][Ring1][=Branch1][Ring1][=Branch2][N][F][O][P][=Branch1][C][=S][Branch2][Ring2][S][O][C][C@@H1][C@H1][Branch2][Ring2][Branch2][C@H1][Branch2][Ring1][Branch2][C@@H1][Branch1][Ring2][O][Ring1][Branch1][N][C][=N][C][=C][Ring1][Branch1][N][=C][Branch1][=Branch1][N][C][Ring1][=Branch1][=O][N][O][P][=Branch1][C][=O][Branch1][Branch1][O][Ring2][Ring2][#Branch2][S][F][O]"}, {"from": "gpt", "value": "A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis."}]